STALLERGENES BECOMES WORLD’S LEADING PRODUCER
- 21/01/2011 |
- 6:17 pm |
- France Biotech
Anthony, France (20 January 2011) Stallergenes S.A. announces the opening of its new raw materials production unit in Amilly, le Loiret (France).This production facility is currently dedicated to the collection and processing of grass pollens used for the manufacture of allergen immunotherapy treatments and, most notably, the grass pollen sublingual immunotherapy tablet, Oralair®.
NanomedTV : Nanobiotix and the ETPN launch
- 20/01/2011 |
- 12:05 pm |
- France Biotech
Paris and Berlin, January the 19th 2011 – Nanomed TV foresees to become the main hub for Nanomedicine thanks to its initiators, two major European players in nanomedicine: the European Technology Platform on Nanomedicine (ETPN) and Nanobiotix. Nanomed TV will make information accessible, aiming at answering what people need and wish to know about Nanomedicine. [...]
Cellectis obtient la licence exclusive des brevets de l’Université du Minnesota sur les effecteurs TAL
- |
- 11:26 am |
- France Biotech
Paris, January 20, 2011 : Cellectis (Alternext: ALCLS), the French genome engineering specialist, has announced today that it has signed an exclusive license agreement with the University of Minnesota that grants Cellectis the worldwide right to use inventions related to TAL effector-mediated DNA recognition and cleavage.
Henri Lachmann entre au Conseil d’administration de CARMAT
- 19/01/2011 |
- 5:07 pm |
- France Biotech
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, today announced the appointment of Henri Lachmann, Chairman of the Supervisory Board of Schneider Electric, to its Board of Directors.
L’efficacité des méganucléases de Cellectis dans la prévention d’infections virales
- |
- 4:27 pm |
- France Biotech
Cellectis’ Meganuclease Technology Used to Efficiently Prevent Viral Infection
IPSOGEN signe un accord avec l’Université de Stanford (USA)
- 18/01/2011 |
- 12:53 pm |
- France Biotech
(Français) Marseille, le 17 Janvier 2011 – IPSOGEN (Alternext – FR0010626028 – ALIPS), profiler de cancers, qui développe, fabrique et commercialise dans le monde entier des tests de diagnostic moléculaire pour les leucémies et le cancer du sein, annonce aujourd’hui la signature d’un accord avec l’Université de Stanford (USA) pour une licence mondiale sur les mutations du gène LNK. La dérégulation de la voie d’activation JAK-STAT liée à l’activation de tyrosines kinases est une caractéristique des syndromes myéloprolifératifs (SMP). La protéine « lymphocyte specific adaptor protein » (LNK) est un facteur de régulation négative de la voie d’activation JAK-STAT et sa modification pourrait représenter un mécanisme alternatif aux mutations JAK2 ou MPL dans la pathobiologie des SMP.
Le CIT participe à un projet de R&D de 10 millions d’euros financé par l’Union européenne et l’industrie cosmétique européenne
- 17/01/2011 |
- 11:36 am |
- France Biotech
CIT joins EUR 10 million R&D project funded by EU and European cosmetic industry
LE NATIONAL CANCER INSTITUTE INITIE UN ESSAI CLINIQUE DE PHASE II AVEC L’ANTICORPS D’INNATE PHARMA IPH 2101
- 13/01/2011 |
- 11:19 am |
- France Biotech
THE US NATIONAL CANCER INSTITUTE STARTS A PHASE II CLINICAL TRIAL WITH INNATE PHARMA’S IPH 2101
Vivalis et Merial signent une nouvelle licence commerciale d’utilisation de la lignée Eb66®
- 11/01/2011 |
- 7:30 pm |
- France Biotech
Nantes, Lyon (France) – January 11, 2011 − VIVALIS, a biopharmaceutical company, announced today that Merial Ltd, a world leader in the veterinary vaccine field, signed a new commercial license for the production of a veterinary vaccine using VIVALIS’ EB66® cell line in last December 2010.
Michael Krel rejoint Deinove en tant que Directeur du Business Development
- |
- 1:05 pm |
- France Biotech
Paris, France, January 11th, 2011 – Deinove (Alternext Paris: ALDEI), the world’s leading specialist in Deinococcus bacteria for biofuels, green chemistry and antibiotics, today announced the appointment of Michael Krel to the newly created post of Executive Vice President, Business Development.
PDF 
